Phase II study of cediranib in patients with advanced gastrointestinal stromal tumors or soft-tissue sarcoma.
Authors
Judson, IScurr, M
Gardner, K
Barquin, E
Marotti, M
Collins, B
Young, H
Jürgensmeier, J
Leahy, Michael G
Affiliation
Royal Marsden Hospital, LondonIssue Date
2014-07-01
Metadata
Show full item recordAbstract
Cediranib is a potent VEGF signaling inhibitor with activity against all three VEGF receptors and KIT. This phase II study evaluated the antitumor activity of cediranib in patients with metastatic gastrointestinal stromal tumor (GIST) resistant/intolerant to imatinib, or metastatic soft-tissue sarcomas (STS; ClinicalTrials.gov, NCT00385203).Citation
Phase II study of cediranib in patients with advanced gastrointestinal stromal tumors or soft-tissue sarcoma. 2014, 20 (13):3603-12 Clin Cancer ResJournal
Clinical Cancer ResearchDOI
10.1158/1078-0432.CCR-13-1881PubMed ID
24714778Type
ArticleLanguage
enISSN
1078-0432ae974a485f413a2113503eed53cd6c53
10.1158/1078-0432.CCR-13-1881
Scopus Count
Collections
Related articles
- Utility of positron emission tomography in sarcomas.
- Authors: Schuetze SM
- Issue date: 2006 Jul
- A phase I study of the HSP90 inhibitor retaspimycin hydrochloride (IPI-504) in patients with gastrointestinal stromal tumors or soft-tissue sarcomas.
- Authors: Wagner AJ, Chugh R, Rosen LS, Morgan JA, George S, Gordon M, Dunbar J, Normant E, Grayzel D, Demetri GD
- Issue date: 2013 Nov 1
- Prospective study of positron emission tomography for evaluation of the activity of lapatinib, a dual inhibitor of the ErbB1 and ErbB2 tyrosine kinases, in patients with advanced tumors.
- Authors: Kawada K, Murakami K, Sato T, Kojima Y, Ebi H, Mukai H, Tahara M, Shimokata K, Minami H
- Issue date: 2007 Jan
- Assessment of early response to imatinib 800 mg after 400 mg progression by ¹⁸F-fluorodeoxyglucose PET in patients with metastatic gastrointestinal stromal tumors.
- Authors: Chacón M, Eleta M, Espindola AR, Roca E, Méndez G, Rojo S, Pupareli C
- Issue date: 2015
- Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria.
- Authors: Choi H, Charnsangavej C, Faria SC, Macapinlac HA, Burgess MA, Patel SR, Chen LL, Podoloff DA, Benjamin RS
- Issue date: 2007 May 1